Search Within

Komal Lachhman Jhaveri

  1. "Breast Medicine Service"
Formats
  1. Meeting Abstract (107)
  2. Journal Article (83)
  3. Review (5)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Breast Medicine Service (199)
  2. Department of Medicine (199)
  3. Solid Tumor Oncology Division (199)
  4. GSK Faculty (57)
  5. Survivorship Research (44)
  6. Epidemiology and Biostatistics (41)

More Groups

People
  1. Shanu Modi (34)
  2. Sarat Chandarlapaty (27)
  3. Clifford Hudis (24)
  4. Pedram Razavi (22)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (5)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (53)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (9)
  5. European Journal of Cancer (5)
  6. Oncology Research and Treatment (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (56)
  2. American Association for Cancer Research (46)
  3. Oxford University Press (23)
  4. Elsevier Inc. (14)
  5. Springer (7)
  6. Nature Publishing Group (6)

More Publishers

Results (199)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis
    Meeting Abstract

    Kümmel, S.; Jhaveri, K.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Thanopoulou, E.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Final OS analysis from the phase 3 TROPiCS-02 study: sacituzumab govitecan in HR+/HER2 - metastatic breast cancer
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Marme, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E.; Dalenc, F.; Pardo, P. G.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Phase Ia/Ib EMBER study
    Journal Article

    Jhaveri, K. L.; Lim, E.; Jeselsohn, R.; Ma, C. X.; Hamilton, E. P.; Osborne, C.; Bhave, M.; Kaufman, P. A.; Beck, J. T.; Sanchez, L. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/Ib trial of inavolisib plus palbociclib and endocrine therapy for PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer
    Journal Article

    Jhaveri, K. L.; Accordino, M. K.; Bedard, P. L.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer
    Journal Article

    Turner, N. C.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Jhaveri, K.; Krivorotko, P.; Loibl, S.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Epichaperome-targeted myocardial imaging by (124)I-PU-H71 PET
    Journal Article

    Mahajan, S.; Grkovski, M.; Staton, K. D.; Ravassa, S.; Domfe, K.; Strauss, H. W.; Humm, J. L.; Zanzonico, P. B.; Beattie, B. J.; Cho, I.; more...
    Clinical and Translational Imaging (2024)

    Fulltext@MSK | Save
  • Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer
    Journal Article

    Turner, N. C.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Sunpaweravong, P.; Musolino, A.; more...
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Journal Article

    Mai, N.; dos Anjos, C. H.; Razavi, P.; Safonov, A.; Patil, S.; Chen, Y.; Drago, J. Z.; Modi, S.; Bromberg, J. F.; Dang, C. T.; more...
    npj Breast Cancer (2024)

    Fulltext@MSK | Save
  • Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study
    Journal Article

    Yonemori, K.; Boni, V.; Min, K. G.; Meniawy, T. M.; Lombard, J.; Kaufman, P. A.; Richardson, D. L.; Bender, L.; Okera, M.; Matsumoto, K.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
    Review

    Lloyd, M. R.; Jhaveri, K.; Kalinsky, K.; Bardia, A.; Wander, S. A.
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save